M
Mark A. Socinski
Researcher at University of North Carolina at Chapel Hill
Publications - 187
Citations - 12685
Mark A. Socinski is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Lung cancer & Carboplatin. The author has an hindex of 55, co-authored 187 publications receiving 11942 citations. Previous affiliations of Mark A. Socinski include Tokyo Institute of Technology & Rush University Medical Center.
Papers
More filters
Journal ArticleDOI
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim,Vera Hirsh,Tony Mok,Mark A. Socinski,Radj Gervais,Yi-Long Wu,Long Yun Li,Claire Watkins,Mark V. Sellers,Elizabeth S. Lowe,Yan Sun,Mei Lin Liao,Kell Østerlind,Martin Reck,Alison Armour,Frances A. Shepherd,Scott M. Lippman,Jean-Yves Douillard +17 more
TL;DR: Non-inferior survival of gefitinib compared with docetaxel is established, suggesting that gef itinib is a valid treatment for pretreated patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
Mark A. Socinski,Igor Bondarenko,Nina Karaseva,Anatoly M. Makhson,Igor Vynnychenko,Isamu Okamoto,Jeremy K. Hon,Vera Hirsh,P. Bhar,Hui Zhang,Jose Iglesias,Markus F. Renschler +11 more
TL;DR: The administration of nab-PC as first-line therapy in patients with advanced NSCLC was efficacious and resulted in a significantly improved ORR versus sb-PC, achieving the primary end point.
Journal ArticleDOI
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
Jean Yves Douillard,Frances A. Shepherd,Vera Hirsh,Tony Mok,Mark A. Socinski,Radj Gervais,Mei Lin Liao,Helge Bischoff,Martin Reck,Mark V. Sellers,Claire Watkins,Georgina Speake,Alison Armour,Edward S. Kim +13 more
TL;DR: Gefitinib can provide similar overall survival to docetaxel in patients across a broad range of clinical subgroups and that EGFR biomarkers such as mutation status may additionally identify which patients are likely to gain greatest PFS and ORR benefit from gefit inib.
Journal ArticleDOI
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts,Mark A. Socinski,Paul Mitchell,Nick Thatcher,Libor Havel,Maciej Krzakowski,Sergiusz Nawrocki,Tudor-Eliade Ciuleanu,Lionel Bosquée,Jose Manuel Trigo,Alexander I. Spira,Lise Tremblay,Jan Nyman,Rodryg Ramlau,Gun Wickart-Johansson,Peter M. Ellis,Oleg Gladkov,José Rodrigues Pereira,Wilfried Eberhardt,Christoph Helwig,Andreas Schröder,Frances A. Shepherd +21 more
TL;DR: The aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy tecemotide improves survival in patients with stage III unresectable non-small-cell lung cancer when given as maintenance therapy after chemoradiation.
Journal ArticleDOI
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.
Mark A. Socinski,Michael J. Schell,Amy H. Peterman,Kamal Bakri,Steven Yates,Robert Gitten,Paul Unger,Joanna Lee,Ji-Hyun Lee,Maureen Tynan,Martha Moore,Merrill S. Kies +11 more
TL;DR: This study shows no overall benefit in survival, response rates, or QOL to continuing treatment with carboplatin/paclitaxel beyond four cycles in advanced NSCLC.